Dh. Grunenwald et al., Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer, J THOR SURG, 122(4), 2001, pp. 796-802
Citations number
20
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Objective: The purpose of this study was to evaluate postchemoradiotherapy
surgery in stage IIIB non-small cell lung cancer.
Methods: Forty patients with stage IIIB non-small cell lung cancer were inc
luded in this phase II study. A preoperative diagnosis of stage IIIB cancer
was based oil mediastinoscopy or a thoracotomy in all patients. Induction
treatment included two cycles of cisplatin (100 mg/m(2), day 1), 5-fluorour
acil (1 g/m(2), days 1-3), and vinblastine (4 mg/m2, day 1) combined with 4
2 Gy of hyperfractionated radiotherapy delivering 21 Gy in two sessions. Pa
tients with a clinical response were offered surgery.
Results: The minimum follow-up for survivors was 48 months. Thirty patients
had a T4 lesion and 18 had N3 disease. Twenty-nine patients (73%) had a cl
inical objective tumor response after induction treatment. These 29 patient
s underwent thoracotomy, and a complete resection was performed in 23 (58%)
. Two postoperative deaths occurred (7%). Four patients had a pathologic co
mplete response at the time of surgery (10%). The 5-year survival is 19% fo
r the overall population. When only patients who had persistent viable tumo
r cells at surgery are considered (n = 25), the 5-year survival is 28%. The
5-year survival is 42% for patients having no mediastinal lymph node invol
vement at the time of surgery and being treated with complete resection.
Conclusion: This study shows that surgery, when feasible, is associated wit
h a 28% long-term survival for patients in whom chemoradiotherapy alone fai
ls to control disease.